Basket | Login | Register


NorAD trial (coming soon)

Phase III trials

Scientific title

Noradrenergic Add-on Therapy With Guanfacine

Study sponsor

Imperial College London


People with a diagnosis of Alzheimer’s Disease


Phase III

Name of drug


Link to full text

Please note that an accessible easy read version of this study is not yet available. The pharmaceutical company running this trial and a member of the European Working Group of People with Dementia are currently reviewing this document.



Last Updated: Wednesday 05 June 2019


  • Acknowledgements

    Alzheimer Europe's Clinical Trial Watch received funding under an operating grant from the European Union’s Health Programme (2014–2020).
  • European Union